Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
NCT ID: NCT03896633
Last Updated: 2023-05-09
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
637 participants
INTERVENTIONAL
2018-02-28
2018-11-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
NCT01722604
A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
NCT05022004
Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes
NCT02512042
To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes
NCT04024072
Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension
NCT00300079
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Azopt 1% ophthalmic suspension
Ophthalmic suspension
Azopt 1%
Azopt 1%, RLD
Brinzolamide 1% ophthalmic suspension
ophthalmic suspension
brinzolamide 1% ophthalmic suspension
brinzolamide 1% ophthalmic suspension
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
brinzolamide 1% ophthalmic suspension
brinzolamide 1% ophthalmic suspension
Azopt 1%
Azopt 1%, RLD
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* diagnosed with primary open-angle glaucoma or ocular hypertension.
Exclusion Criteria
* ocular hypertension.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bausch & Lomb Incorporated
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lindsey Mathew
Role: STUDY_DIRECTOR
Bausch Health Americas, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Various
Bridgewater, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
883
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.